Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2026 08:40 ET | Source: Senti Biosciences, Inc.

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep...
May 14, 2026 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026Announced...
May 14, 2026 08:00 ET | Source: Cingulate Inc.

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to...
May 14, 2026 08:00 ET | Source: MeiraGTx

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced...
May 14, 2026 07:22 ET | Source: SNS Insider pvt ltd

Genomic Medicine Market Size to Reach a Valuation of USD 123 Billion by 2035; Increasing Utilization of Personalized Medicine Methodologies Boost Growth Globally

Global Genomic Medicine Market to reach USD 123 billion by 2035, driven by rising cancer cases and growing adoption of precision medicine.
May 14, 2026 07:01 ET | Source: Invivyd

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued...
May 14, 2026 07:00 ET | Source: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential...
May 14, 2026 07:00 ET | Source: Cyclarity Therapeutics

Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions

Safe excretion of 7KC, a core driver of plaque associated with heart disease, stroke, inflammation, and age-related diseases, in humans suggests medicine could move beyond slowing heart disease to...
May 14, 2026 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Autolus Therapeutics announced its operational and financial results for the first quarter ended March 31, 2026.
May 14, 2026 06:01 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new...